Table 3.

Factors associated with 30-day mortality by univariate analysis in patients with IC

Variable	30-day outcome		P-value
	Survived (n = 213)	Died (n = 30)
Age,years (range)	57.8(17–91)	62.7(29–81)	0.127
Gender (male:female)	124:89	15:15	0.394
Underlying comorbidities (n, %)
Gastrointestinal perforation	39 (18.3)	9 (30.0)	0.132
Respiratory dysfunction	31 (14.6)	20 (66.7)	< 0.001
Pulmonary infection	63 (29.6)	18 (60.0)	0.001
Cardiovascular disease	58 (27.2)	20 (66.7)	< 0.001
Neurological diseases	47 (22.1)	11 (36.7)	0.079
Gastrointestinal pathology	56 (26.3)	7 (23.3)	0.729
Chronic/acute liver disease	36 (16.9)	9 (30.0)	0.084
Chronic/acute renal failure	74 (34.7)	16 (53.3)	0.048
Solid tumour	19 (8.9)	3 (10.0)	0.847
Haematological malignancy	5 (2.3)	1 (3.3)	0.991
Severe autoimmune diseases	8 (3.8)	3 (10.0)	0.124
Diabetes mellitus	79 (37.1)	14 (46.7)	0.312
Burns	5 (2.3)	1 (3.3)	0.745
HIV/AIDS	11 (5.2)	2 (6.7)	0.732
Severe trauma	13 (6.1)	2 (6.7)	0.904
Risk factors (n,%)
Presence of CVC	104 (48.8)	14 (46.7)	0.825
Mechanical ventilation	67 (31.5)	15 (50.0)	0.044
Receipt of corticosteroids	58 (27.2)	12 (40.0)	0.148
Total parenteral nutrition	100 (46.9)	19 (63.3)	0.093
Chemotherapy	10 (4.7)	1 (3.3)	0.737
Abdominal surgery	67 (31.5)	2 (6.7)	0.005
In the ICU at diagnosis	30 (14.1)	12 (40.0)	< 0.001
Neutropenia	5 (2.3)	2 (6.7)	0.185
Concomitant bacterial infections	67 (31.5)	14 (46.7)	0.098
Septic shock	35 (16.4)	11 (36.7)	0.008
Dialysis	21 (9.9)	4 (13.3)	0.558
Prior exposure to broad-spectrum antibiotics	188 (88.3)	27 (90.0)	0.780
Treatment with antifungal agents	71 (33.3)	12 (40.0)	0.471
Species, n (%)
C. albicans	90 (42.3)	20 (66.7)	0.012
C. glabrata	67 (31.5)	6 (20.0)	0.200
C. tropicalis	34 (16.0)	3 (10.0)	0.395

ICU intensive care unit, CVC central venous catheter